Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
63 hedge funds and large institutions have $39.3M invested in Kronos Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 20 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.92% less ownership
Funds ownership: 54.82% → 51.9% (-2.9%)
21% less funds holding
Funds holding: 80 → 63 (-17)
28% less capital invested
Capital invested by funds: $54.3M → $39.3M (-$15M)
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
85% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$652K |
| 2 |
Millennium Management
New York
|
+$572K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$292K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$148K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cerity Partners
New York
|
-$730K |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$562K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$374K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$367K |
| 5 |
Renaissance Technologies
New York
|
-$316K |
KRON Hedge Fund Activity: Q3 2023 in Review
63 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q3 2023, worth a combined $39.3M — down 28% from $54.3M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KRON and 3 opened new positions — a net loss of 17 holders — while 21 trimmed existing stakes and 13 added.
The largest buyer was Acuta Capital Partners, adding an estimated $652K. The largest seller was Cerity Partners, exiting entirely with an estimated $730K sold.
- 63 institutional investors held Kronos Bio (KRON) as of Q3 2023, down from 80 in Q2 2023.
- Funds reported $39.3M of Kronos Bio stock for Q3 2023, down 28% quarter-over-quarter.
- 3 funds opened new Kronos Bio positions in Q3 2023 and 20 closed out, a net change of -17 holders.
- The largest Kronos Bio buyer in Q3 2023 was Acuta Capital Partners, an estimated $652K added.
- The largest Kronos Bio seller in Q3 2023 was Cerity Partners, an estimated $730K sold.
Based on aggregated 13F filings for Q3 2023.